鲑鱼降钙素PLGA微球缓释载体 Salmon Calcitonin-Loaded PLGA Microspheres as a Sustained-Release Vehicle

本文制备六种不同分子量和末端基团的载鲑鱼降钙素PLGA微球(SCT-PLGA MS)，优选合适微球用于废用性骨质疏松症在骨折损伤部位缓释药物。载药微球平均粒径均为120 μm，形态圆整；包封率均高于60%，载药量约为0.5%；差示扫描量热(DSC)测试结果表明SCT包载在于PLGA微球中，并以无定形态存在；体外释放结果表明分子量为20 kDa的-COOH末端载药微球(SCT-PLGA-20 COOH MS) 40 天累积释放百分率达79%以上，具有良好的缓释作用；体外降解中SCT-PLGA-20 COOH MS pH值随时间延长下降速率高于其他微球。因此，本研究中SCT-PLGA-20 COOH MS有望用于治疗废用性骨质疏松症。 In this study, to optimize appropriate poly(d,l-lactic-co-glycolic acid) microspheres (PLGA MS) to release SCT in the treatment of disuse osteoporosis, six kinds of SCT-PLGA MS with different mo-lecular weight and terminal groups were prepared. SCT-PLGA MS had an average particle size of about 120 μm, an encapsulation efficiency of 60%, and a drug loading of 0.5%. The result of differential scanning calorimetry (DSC) evidenced that SCT had been entrapped as an amorphous form in MS matrix. For SCT-PLGA-20 COOH MS, the cumulative release was above 79% at 40 d. PH value of SCT-PLGA-20 COOH MS decreased more rapidly than that of MS with -CH3 in the degradation. In conclusion, SCT-PLGA-20 COOH MS is promising in the treatment of disuse osteoporosis.